Recently, the phase-II trial of toripalimab plus chemotherapy as a second-line treatment in previously EGFR-TKI-treated patients with EGFR-mutant advanced NSCLC showed results with an overall ORR of 50.0% and DCR of 87.5%. Here, EGFR is linked to non-small cell lung carcinoma.